TGA approves oral GLP-1 drug Foundayo for type 2 diabetes and weight management
Juste les faits

TGA approves oral GLP-1 drug Foundayo for type 2 diabetes and weight management

Résumé

The Therapeutic Goods Administration has approved Foundayo, an oral GLP-1 receptor agonist, offering a daily tablet option for eligible adults with type 2 diabetes and obesity.

The Therapeutic Goods Administration approved Foundayo (orforglipron) on 16 November 2026, adding an oral GLP-1 receptor agonist to the range of treatments for type 2 diabetes and chronic weight management in eligible adults. The medication can be taken once daily without specific food or water restrictions, providing an alternative to injectable GLP-1 therapies.

Diabetes Australia Group CEO Justine Cain said the approval expands options for people living with type 2 diabetes and obesity, but cautioned that regulatory approval does not guarantee affordable or equitable access.

"GLP-1 medicines have significantly expanded treatment options for many people living with type 2 diabetes and obesity, and it is encouraging to see new formulations becoming available," Cain said.

"Importantly, regulatory approval does not automatically mean that a medicine will be affordable or equitably accessible to everyone who could benefit. As new treatments emerge, we need to ensure that decisions about access and affordability are guided by strong clinical evidence and health need, rather than a person’s capacity to pay.

"For some people, the cost of these medicines remains a significant barrier. We need to continue looking at evidence-based approaches to subsidised access so that people who are clinically most likely to benefit are not excluded because they cannot afford treatment. Innovation is important, but so is equitable access. A treatment can only improve health outcomes if the people who stand to benefit can actually access it."

Cain also highlighted the need for comprehensive, person-centred care, noting that expanded access to GLP-1 medicines should be accompanied by appropriate clinical support, nutrition, physical activity guidance, psychological assistance where needed, and long-term follow-up. She stressed that appropriate prescribing and safe use are essential to maximise health benefits.

The TGA approval and registration on the Australian Register of Therapeutic Goods are separate from any subsidy through the Pharmaceutical Benefits Scheme. Diabetes Australia advises individuals to consult their GP, endocrinologist, pharmacist or other qualified health professional to discuss the potential benefits, risks and suitability of GLP-1 treatments.

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.